Lipitor Faces Tough Competition From Generic Versions
Submitted by Prakash Sharma on Tue, 12/20/2011 - 09:45In a recent report, it has been made clear that the sales of cholesterol blockbuster Lipitor have tumbled down by 50% in a single week as the market is flooded with new prescriptions for generic Lipitor. Though stern efforts were made by Lipitor maker Pfizer to ensure that patients stray with their pull, it was observed that majority of the patients had switched their preference.
Not Able to Launch Flomax Generic Across US, Ranbaxy Says
Submitted by Amit Pathania on Wed, 03/03/2010 - 17:20On Wednesday, Ranbaxy Laboratories said that it would not be able to introduce a generic variant of a urinary medicine in the US as per schedule, as there has not been a final approval from the regulator yet.
Not Able to Launch Flomax Generic Across US, Ranbaxy Says
Submitted by Jason Ramsey on Wed, 03/03/2010 - 10:43On Wednesday, Ranbaxy Laboratories said that it would not be able to introduce a generic variant of a urinary medicine in the US as per schedule, as there has not been a final approval from the regulator yet.
Ranbaxy gets nods for Quinapril & HCTZ Tablets
Submitted by Amit Pathania on Thu, 03/05/2009 - 21:16India'a largest pharmaceutical company Ranbaxy Laboratories Ltd has finally got nod from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) and Quinapril Hydrochloride & Hydrochlotothiazide (Quinapril + HCTZ) Tablets, an ACE inhibitor which is used to treat high blood pressure.
New Applications from a Ranbaxy Plant Halted by FDA
Submitted by Amit Pathania on Thu, 02/26/2009 - 11:01U. S. health officials said the review of any new drug applications from a Ranbaxy Laboratories plant in India has been halted after it was discovered that scientific data was falsified.












